Jubilant renames HollisterStier Contract Manufacturing

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical drug

Indian CRAMS firm Jubilant Life Sciences has renamed HollisterStier Contract Manufacturing and hired a new BD exec in latest stage of North American reorganisation.

Jubilant bought Hollister, which will now operate as Jubilant HollisterStier Contract Manufacturing and Services (JHSCMS), in 2007 for $122m in what was then its largest acquisition in North America.

Since then the Indian contract research and manufacturing services (CRAMS) has slowly been integrating Hollister, along with subsequent acquisition Draxis Specialty Pharmaceutical​, into its wider business.

This process began in 2008 when Jubilant split operations into two units: Specialty Pharmaceuticals, combining the radiopharma business of Draxis​ and the allergy extracts business of Hollister; and contract manufacturing.

JHSCMS is part of the contract manufacturing group, which combines its sterile injectables manufacturing arm with the sterile injectable, semi- solids and solid dose manufacturing operations of Draxis.

Q4 CMO revs down

The rebranding comes just a few weeks after Jubilant reported a disappointing set of quarterly results for its contracting business.

Total revenue from the firm’s life science business, combining services and products, grew 12 per cent in the three months ended March 31 to Rs698crores, as a result of demand for APIs and generics.

However, the contribution from Jubilant’s services business, with includes its contract manufacturing division, was Rs192crores ($42.6m), down RS92crore on the final quarter of fiscal 2010.

The firm attributed the decline, which continued the pattern seen in Q3​, to a slowdown in demand and the fact the year-earlier quarter included revenue from the supply of H1N1 vaccine related manufacturing.

Managing director Shyam Bhartia ​said: "In Financial Year 2011 the Company has recorded a good revenue growth in Products business driven by a robust volume growth of 16% across the products.

However​,” he continued “the growth in Service business is muted due to one-time revenue opportunity in previous year and slowdown in Clinical Research business.

“In FY2012, we expect to deliver a robust sales growth and better margins across all the businesses on account of increased capacity utilisation, commissioning of new plants, innovation led new launches and expansion of market geographies.

Perhaps with this in mind Jubilant has hired David Linn as JHSCMS’ new director or business intelligence and business development.

Prior to joining JHSCMS Linn has senior director o market and business development at DSM Pharmaceutical, with responsibility for the the Dutch firm’s finished dosage form business.

Related news

Show more

Related product